quantisnow
FeedTopReportsPricing
⌘K
Live feed
13:00:33·27d
SECFiling
Monopar Therapeutics Inc. logo

SEC Form 10-K filed by Monopar Therapeutics Inc.

MNPR· Monopar Therapeutics Inc.
Health Care
Original source

Companies

  • MNPR
    Monopar Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jan 9UpdateMorgan Stanley$115.00
  • Nov 14UpdateRaymond James-
  • Nov 10UpdateLeerink Partners$115.00
  • Oct 13UpdateBarclays$125.00
  • Sep 9UpdateBTIG Research$87.00
  • Sep 3UpdateOppenheimer$77.00

Related

  • SEC3d
    Monopar Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
  • PR4d
    Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
  • INSIDER21d
    SEC Form 4 filed by Robinson Chandler
  • INSIDER21d
    SEC Form 4 filed by Cittadine Andrew
  • SEC22d
    Amendment: SEC Form 10-K/A filed by Monopar Therapeutics Inc.
  • SEC27d
    Monopar Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR27d
    Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
  • INSIDER50d
    SEC Form 4 filed by CCSO Rodriguez Susan
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022